{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":300,"width":600,"title":" Stent. Relieve. Revive: EVT Rewrites the Story of Post-Thrombotic Syndrome \ud83e\ude7a\u26a1","description":"A thoughtful, practice-shaping study in NEJM explores a long-standing clinical dilemma: can we truly move the needle in post-thrombotic syndrome?   The C-TRACT trial shows that endovascular therapy (iliac-vein stenting) significantly improves symptom burden and quality of life in patients with moderate\u2013severe disease\u2014measured rigorously using VCSS, VEINES-QOL, and SF-36. The magnitude of benefit is clinically meaningful.   But every intervention casts a shadow.   \ud83d\udc49 Bleeding risk was ~3-fold higher, largely driven by intensified antithrombotic therapy. \ud83d\udc49 Durability beyond 6 months remains unknown.   This is not a simple \u201cyes or no\u201d trial\u2014it is a study in nuance, trade-offs, and patient-centered decision making.   For the right patient\u2014severe symptoms, clear iliac obstruction, acceptable bleeding risk\u2014EVT may offer a path from limitation to liberation.   The vein opens. The patient breathes. The clinician pauses.   Science advances not in absolutes\u2014but in balance. \u2696\ufe0f\ud83e\ude7a ","author_name":"Dr. RR Baliga's 'Podkast for the Kurious Doc'","author_url":"http:\/\/www.MasterMedFacts.com","html":"